MERIT MEDICAL SYSTEMS INC (MMSI)
Health Care · Medical Devices · NASDAQ
Merit Medical provides a broad range of proprietary medical devices used globally in minimally invasive interventional and diagnostic procedures.
What MERIT MEDICAL SYSTEMS INC does
Merit Medical Systems is a manufacturer and marketer of proprietary medical devices for interventional, diagnostic, and therapeutic procedures. The company operates through two primary product categories—foundational and therapeutic—serving clinical specialties including cardiology, radiology, oncology, critical care, and endoscopy.
Themes: interventional cardiology, minimally invasive surgery, oncology diagnostics, endoscopy, critical care medical technology, medical device OEM services
Fundamentals
- Price$85.25 as of 2026-10-08 close
- Market cap$5.1B as of 2026-07-28 (share count; price 2026-10-08)
- 1-year return+1.8% 2025-10-08 close $83.74 → 2026-10-08 close $85.25
- P/E35.14 as of 2026-10-08
- Net margin+8.5% FY2025, SEC XBRL
- Gross margin+48.7% FY2025, SEC XBRL
- ROE+8.1% FY2025, SEC XBRL
- Debt / equity0.44 as of 2026-09-03
- Revenue growth (YoY)+10.2% as of 2026-09-03
- Revenue CAGR (3y)+9.6% SEC XBRL
- Beta0.75 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How MMSI compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MMSI is not currently in any published Top 10 list. Its scores are below.
Top 10 score
51.3 #655 of 1,379 scored · #81 of 151 in Health Care
Trend 64th (it is 10.0% below its highest point of the past year) and financial health 60th (free cash flow margin 14.2%, debt to equity 0.4); weakest is capital return (21st, consecutive years of dividend increases 0 years, net share count bought back over the year -1.8).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How MERIT MEDICAL SYSTEMS INC looks technically
MERIT MEDICAL SYSTEMS INC (MMSI) is trading 10.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 10.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +10.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $87.96 | $87.96 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $77.00 | $77.00 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 84.12. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal | 35 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 43.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($84.03 to $88.90) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 25.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 37 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $94.75 | $94.75 |
|---|---|---|
| From the 52-week high | it is 10.0% below its 52-week high (its highest price of the past year) | -10.0% |
| Above the 52-week low | it is 42.7% above its 52-week low (its lowest price of the past year) | +42.7% |
| Below the 52-week high | it is 10.0% below its highest point of the past year | 10.0% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 36 trading days ago | 36 sessions |
| All-time high | its highest closing price on record is $111.45 (set on 2025-01-31) | $111.45 |
| Given back of the 52-week move | over the past year its closes ranged ($60.31 to $93.18), and it has recovered well over two thirds of its fall from last year’s high — 76% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $80.62 to $81.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 75.9% |
| From the all-time high | it is 23.5% below its all-time high | -23.5% |
| Nearest price level | it is trading 0.6% above a support level at $84.74 — a price it turned at 8 times since 2025-04-09, most recently on 2026-09-18. Since 2024-10-08 it has 7 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.6% |
| All-time low | its lowest closing price on record is $7.66 (set on 2009-03-09) | $7.66 |
| Above the all-time low | it is 1013.5% above its all-time low | +1,014% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 5% of the past ~6 months), which often precedes a bigger move | 5th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.02 between its high and its low — about 2.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.02 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $84.56 and $88.08 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $84.56 – $86.32 – $88.08 |
| Typical daily range (% of price) | its price moves about 2.4% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.4% |
| Stretch from the 200-day average | it is trading 4.1 daily ranges above its 200-day average price (10.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.90× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 5.2% gap up opened on 2026-07-31 has been "filled" 48 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 48 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +0.34% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.5 percentage points (the stock lost 2.4% while the market gained 1.0%) | -3.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.1 percentage points (the stock gained 20.0% while the market gained 3.8%) | +16.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 8.3 percentage points (the stock gained 25.7% while the market gained 17.5%) | +8.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 13.2 percentage points (the stock gained 1.8% while the market gained 15.0%) | -13.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 10.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $76.48 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +11.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $87.76 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -2.9% |
Price levels it has turned at before
MMSI last closed at $85.25 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $84.74 | Support | 0.6% below the last close | turned there 8 times · 2025-04-09 to 2026-09-18 |
| $82.77 | Support | 2.9% below the last close | turned there twice · 2025-07-21 to 2025-12-08 |
| $81.34 | Support | 4.6% below the last close | turned there three times · 2025-07-31 to 2025-10-30 |
| $89.22 | Resistance | 4.7% above the last close | turned there six times · 2025-04-21 to 2026-08-18 |
| $91.70 | Resistance | 7.6% above the last close | turned there six times · 2025-05-06 to 2026-09-02 |
| $94.39 | Resistance | 10.7% above the last close | turned there six times · 2024-10-23 to 2026-01-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $84.12.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $116.28 and $136.16 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $84.12.
This reading has stood for 16 trading days, since 2026-09-17.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke down to a new 20-day low · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · beating the market · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.82 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$101.45 range $83.00 – $123.00; median $100.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MMSI
- Consensus EPS estimate$1.03 next reporting period, as of 2026-10-03
- Estimate change, 30 days$0.00 (0.0%) from $1.03, on 2026-08-29, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant uncertainty regarding the recovery of historically paid tariffs and the impact of future regulatory or trade policy changes.","Exposure to foreign currency exchange rate fluctuations affecting international sales."]
What changed in the latest 10-Q
AI-assisted comparison of MMSI's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Business structure reorganized into 'foundational' and 'therapeutic' product categories (2026) replacing prior 'cardiovascular' and 'endoscopy' segments
- Foundational product category includes access devices, procedural solutions, OEM products, and vascular intervention platforms
- Therapeutic product category includes cardiac therapies, oncology, renal therapies, vascular intervention, OEM products and endoscopy platforms
- Three-month period ended March 31, 2026 sales of $381.9 million, up 7% versus March 31, 2025
- Q1 2026 net income of $41.0 million or $0.68 per share versus Q1 2025 net income of $30.1 million or $0.49 per share
- Cash, cash equivalents, and restricted cash of $490.2 million as of March 31, 2026
- February 20, 2026 U.S. Supreme Court ruling on tariffs under International Emergency Economic Powers Act (IEEPA)
- Company is importer of record for certain raw materials and products previously subject to IEEPA tariffs
- Biolife Merger acquisition of StatSeal and WoundSeal products mentioned in access platform discussion
- View Point Acquisition pending as of March 31, 2026
- C2 Cryoballoon acquisition from Pentax driving endoscopy sales increases
- SG&A expenses increased $10.7 million or 10.0% for Q1 2026 versus Q1 2025
- International sales increased in Europe, Middle East and Africa, Rest of World and Asia Pacific regions
- Removed:
- Cardiovascular segment organizational structure removed
- Endoscopy segment organizational structure removed
- Four product categories under cardiovascular segment (peripheral intervention, cardiac intervention, custom procedural solutions, OEM) removed as primary structure
- Reference to 'Risk Factors' in 2024 Annual Report on Form 10-K removed (replaced with 2025 Annual Report)
- Reference to Part II, Item 1A 'Risk Factors' in quarterly reports for March 31, 2025 and June 30, 2025 removed
- Three and nine-month period ended September 30, 2025 sales data removed
- September 30, 2025 cash position of $394.6 million removed
- Generic trade policy discussion about tariff increases and retaliatory measures removed
- Nine-month period operational metrics removed (newer filing shows only three-month data)
- Reworded:
- Reference year for 'Risk Factors' changed from '2024 Annual Report on Form 10-K' to '2025 Annual Report on Form 10-K'
- Period reference changed from 'three-month period ended September 30, 2025' to 'three-month period ended March 31, 2026'
- Tariff discussion changed from general trade policy uncertainty to specific February 20, 2026 Supreme Court ruling on IEEPA tariffs
- SG&A expense discussion expanded to include specific drivers: commissions, headcount additions, acquisition-related costs, and View Point Acquisition costs
- Gross profit percentage remains 48.4% (unchanged between comparable quarters but reporting periods differ)
- Notes:
- The two filings represent different fiscal periods (Q1 2026 versus Q3 2025) with fundamentally different time reference points, making direct operational comparisons limited
- The older filing text appears truncated at the end ('which inc'), affecting completeness of comparison
- The newer filing MD&A text also appears truncated near the end ('and compan'), limiting full assessment of all changes
- Business reorganization from segment-based (Cardiovascular/Endoscopy) to category-based (Foundational/Therapeutic) structure is a material change in reporting but both versions describe the same underlying business
Risk Factors
- Added:
- New risk factor added in 2026-04-30 filing: 'The conflict among the United States, Israel and Iran and related geopolitical instability may adversely affect our business' describing February 2026 military strikes, potential impacts on energy supplies, inflation, supply chains, and macroeconomic conditions.
- Item 5(a)(i) added employment agreement disclosures for Raul Parra, Brian G. Lloyd, Neil W. Peterson, and Michel J. Voigt effective May 1, 2025.
- Item 5(a)(ii) added Performance Stock Unit Award Agreements and Restricted Stock Unit Award Agreements dated February 26, 2026 for Martha G. Aronson, Raul Parra, Brian G. Lloyd, Neil W. Peterson, and Michel J. Voigt.
- Item 5(a)(iii) added Retention Restricted Stock Unit Award Agreements dated February 26, 2026 for Raul Parra, Brian G. Lloyd, and Michel J. Voigt.
- Exhibits 10.2-10.5 added: Amended and Restated Employment Agreements for Raul Parra, Brian G. Lloyd, Neil W. Peterson, and Michel J. Voigt.
- Exhibits 10.6-10.15 added: Performance Stock Unit Award Agreements and Restricted Stock Unit Award Agreements for Martha Aronson, Raul Parra, Brian Lloyd, Neil Peterson, and Mike Voigt.
- Exhibits 10.16-10.17 added: Retention Restricted Stock Unit Award Agreements for Raul Parra, Brian Lloyd, and Mike Voigt.
- Removed:
- Risk factor 'If we are unable to effectively execute our leadership succession plans and attract, develop and retain key employees, our business and results of operations could be harmed' removed from 2026 filing.
- Exhibits 10.1-10.6 from 2025 filing removed (Martha G. Aronson CEO Employment Agreement dated October 3, 2025; PSU and RSU agreements for Aronson dated October 3, 2025; CEO Transition Agreement for Fred P. Lampropoulos; Employment Agreement for Christian Adam Smith; and Indemnification Agreement for Christian Adam Smith).
- Exhibits 31.2 and 32.1-32.2 (CFO and CEO certifications) removed from exhibit list in 2026 filing.
- Exhibit 101 and 104 (iXBRL financial data exhibits) removed from exhibit list in 2026 filing.
- Reworded:
- Reference year changed from '2024 Annual Report on Form 10-K' to '2025 Annual Report on Form 10-K' in Item 1A opening paragraph.
- Removed reference to 'Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2025 and June 30, 2025' in Item 1A.
- Item 5(b) reporting period changed from 'three-month period ended September 30, 2025' to 'three-month period ended March 31, 2026'.
- Exhibit 10.1 description changed: 2025 filing referenced 'Chief Executive Officer Employment Agreement, dated October 3, 2025, by and between Merit Medical Systems, Inc. and Martha G. Aronson'; 2026 filing references 'Consulting Agreement, dated January 7, 2026, between Merit Medical Systems, Inc. and Fred P. Lampropoulos'.
- Notes:
- The 2025 filing included full signature blocks and iXBRL exhibit details; the 2026 excerpt appears truncated and does not include complete signature section or all exhibit details, limiting full comparison of those sections.
- The leadership succession risk factor was replaced with a new geopolitical risk factor rather than updated, representing a substantive topic shift.
- Employment agreement documents themselves are incorporated by reference in the Proxy Statement rather than fully detailed in Item 5 of the 2026 filing.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 2 sells ($3M) — 1 selling insider
- Last 180 days · read to 2026-10-045 buys ($573294) · 3 sells ($3M) — 5 buying, 2 selling insiders
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of MMSI within a 30-day window between 2026-05-05 and 2026-05-11. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-24. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MMSI's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for MMSI from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding MMSI as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 14,955,535
- Reported value $1,037,036,589
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MMSI's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MMSI had 3,934,838 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
MMSI had 6.59% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 6 days to cover at the same settlement.
- Reported short interest (shares) 3,934,838
- Short interest (% of shares outstanding) 6.59%
- Prior settlement (shares) 3,617,141
- Reported change 8.78%
- Days to cover (reported) 6
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Boston Scientific (BSX)
- Cook Medical
- Edwards Lifesciences (EW)
- Teleflex (TFX)
- Becton Dickinson (BDX)
- Johnson & Johnson (JNJ)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MMSI vs…
MERIT MEDICAL SYSTEMS INC is found in…
Frequently asked questions
What does MERIT MEDICAL SYSTEMS INC (MMSI) do?
Merit Medical Systems is a manufacturer and marketer of proprietary medical devices for interventional, diagnostic, and therapeutic procedures. The company operates through two primary product categories—foundational and therapeutic—serving clinical specialties including cardiology, radiology, oncology, critical care, and endoscopy.
What sector is MERIT MEDICAL SYSTEMS INC (MMSI) in?
MERIT MEDICAL SYSTEMS INC (MMSI) is classified in the Health Care sector. Its industry is Medical Devices. It trades on NASDAQ.
Who are MERIT MEDICAL SYSTEMS INC's (MMSI) competitors?
Notable peers of MERIT MEDICAL SYSTEMS INC (MMSI) include Boston Scientific, Cook Medical, Edwards Lifesciences, Teleflex and Becton Dickinson. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in MMSI?
Yes — we hold 2 matched STOCK Act disclosures for MMSI from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is MERIT MEDICAL SYSTEMS INC (MMSI) overbought or oversold right now?
MERIT MEDICAL SYSTEMS INC (MMSI) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MMSI come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.